Vascular Solutions acquires EXPRO Elite and MICRO Elite snare products from Radius

NewsGuard 100/100 Score

Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it has acquired the assets related to the EXPRO Elite™ and MICRO Elite™ snare products from Radius Medical Technologies, Inc. and its subsidiary, Radius Medical, LLC. Vascular Solutions has been selling the EXPRO Elite™ and MICRO Elite™ snares in the U.S. under a distribution relationship with Radius since 2008, while in international markets Radius has been selling the products through a network of independent distributors. Sales of the products were $1.6 million during the last four quarters, consisting of $1.3 million in sales in the U.S. and $0.3 million in sales to distributors in international markets. Effective immediately, international sales of the snare products will transition to Vascular Solutions' existing international distribution network and U.S. sales will continue to be sold through Vascular Solutions' direct sales force. Also included in the asset acquisition are the QUATTRO Elite™ and SYMPRO Elite™ snares and the Oracle™ retrieval system, all of which are either recently launched or in development.

“We are excited about owning the EXPRO Elite and MICRO Elite snares and capturing the entire margin on the sale of the product while adding international sales”

Vascular Solutions expects to transfer the manufacturing of the products from Radius' facility in Boston to Vascular Solutions' existing facility in Minnesota over the next six months. The aggregate acquisition price of $6.5 million consists of $5.0 million paid in cash at closing and $1.5 million payable in cash upon successful completion of the transfer of the manufacturing processes. In addition, Radius will be entitled to receive a cash earn-out payment following each of calendar years 2011, 2012 and 2013, in each case in an amount equal to 25% of net sales for that calendar year in excess of a target amount. The target amount is $2,000,000, $2,500,000 and $3,000,000 for calendar years 2011, 2012 and 2013, respectively.

"We are excited about owning the EXPRO Elite and MICRO Elite snares and capturing the entire margin on the sale of the product while adding international sales," commented Howard Root, Chief Executive Officer of Vascular Solutions. "Upon completion of the manufacturing transfer we expect to be able to both improve our gross margin and adopt more competitive pricing to gain market share in the existing $35 million snare market. We also look forward to launching the QUATTRO Elite and SYMPRO Elite snares either late this year or early in 2011 and to explore the possibilities with the Oracle retrieval system. We expect the acquisition will be accretive to our earnings by approximately $0.02 per share in 2011, with only modest transition and integration costs in the fourth quarter of 2010," Mr. Root added.

The acquisition will be accounted for as a business combination in the fourth quarter of 2010. On a preliminary basis, approximately $1.0 million will be allocated to the earn-out value, thereby increasing the total estimated purchase price to $7.5 million. Approximately $150,000 of the acquisition price is expected to be allocated to the tangible assets acquired in the transaction, with $3.2 million allocated to intangible assets and the remaining $4.2 million allocated to goodwill. The intangible assets are expected to be amortized at the rate of approximately $80,000 per quarter.

Source:

Vascular Solutions, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer